Sotiris Kyriakou

Dr. Sotiris Kyriakou

William Harvey Research Institute, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GZGönül Zeren
Gönül Zeren
EBEREN OZAN BAKIR
EREN OZAN BAKIR
VTVincenzo Tufaro
Vincenzo Tufaro
AİAyşe Nur Özkaya İbiş
Ayşe Nur Özkaya İbiş
TZTingquan Zhou
Tingquan Zhou
Christos BourantasChristos Bourantas
Christos Bourantas
Intravascular imaging (IVI) was introduced 35 years ago to assess coronary artery pathology and plaque vulnerability. However, from its first applications it became apparent that it can also be useful in percutaneous coronary intervention (PCI) planning and optimizing PCI results. In the early days of PCI, IVI was used to examine the efficacy of emerging endovascular devices and the vessel wall response to therapy, while in the drug-eluting stent (DES) era, IVI was used to guide DES implantation and assess final results post-intervention. The first studies assessing the role of IVI in guiding PCI with DES have failed to demonstrate a prognostic benefit for the use of IVI; however, more recent large-scale randomized trials have underscored its value in this setting. IVI, with its high resolution, allows optimal stent sizing, prompt identification and correction of common causes of stent failure, and it has been shown that it improves outcomes in complex procedures. This review summarizes the evidence supporting the role of IVI in PCI planning in DES era, synopsizes the studies that have highlighted the value of IVI in predicting stent failure, discusses the limitations of the first randomized trials that failed to demonstrate a prognostic benefit from its use, and presents the results of the more recent large-scale outcome studies that underscored its role in complex PCI planning.

Verified
Journal Article
Open access
PDF file
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
MMMarios Markantonis
Marios Markantonis
PGPanos Georghiou
Panos Georghiou
FTFilippos Triposkiadis
Filippos Triposkiadis
AGAmalia Georgiou
Amalia Georgiou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Postoperative atrial fibrillation (POAF) is the most frequent post-cardiac surgical arrhythmia and is associated with haemodynamic instability, longer hospital stays, higher healthcare utilisation, stroke and adverse long-term outcomes. Conventional models of POAF focus on advancing age, pre-existing atrial substrate, increasing operative complexity, inflammatory responses related to cardiopulmonary bypass, disturbances in autonomic balance, and acute metabolic insults during the perioperative period. Although these explanations are important, they may be incomplete. Malignancy and the cancer-associated systemic environment involve biological processes potentially relevant to postoperative atrial vulnerability, such as chronic inflammation, oxidative stress, impaired vascular function, hypercoagulability, altered immune response, frailty, and treatment-related myocardial, pericardial, or conduction-system injury. This review assesses whether malignancy should be regarded as an underrecognised modifier of susceptibility rather than as a coincidental comorbidity. Most available data are extrapolated from cardio-oncology and thoracic oncology studies or general studies related to atrial fibrillation (AF) rather than studies focused on cardiac surgery. While malignancy cannot be dismissed as irrelevant to the generation of POAF, it also does not permit causal inference. Future studies should move beyond binary cancer status and incorporate cancer activity, treatment exposures, biomarker profiles, and atrial substrate measures to determine whether malignancy improves perioperative POAF risk stratification.

22 October 2025 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Open access
NYNathan Angelo Lecaros Yap
Nathan Angelo Lecaros Yap
XHXingwei He
Xingwei He
ITIbrahim Halil Tanboga
Ibrahim Halil Tanboga
ARAnantharaman Ramasamy
Anantharaman Ramasamy
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
Christos BourantasChristos Bourantas
Christos Bourantas
To evaluate the performance of various computed tomography angiography (CTA) reconstruction methods in assessing coronary plaque composition using near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS) as the reference standard. Fifteen patients with chronic coronary syndrome underwent CTA and 3-vessel NIRS-IVUS imaging. CTA datasets were reconstructed using a medium-smooth b40f kernel with two slice thicknesses, 0.75 ​mm and 0.50 ​mm, and three strengths of advanced model-based iterative reconstruction (ADMIRE). Plaque components on CTA were classified using fixed and adaptive Hounsfield unit (HU) thresholds while NIRS-IVUS classification employed a deep learning method validated against histology. Matched CTA and NIRS-IVUS images were analyzed to quantify fibrotic tissue (FT), necrotic core (NC), and calcific (Ca) volumes and areas at both segment- and lesion-level. The intraclass correlation coefficient (ICC) and Surface Under the Cumulative Ranking Curve (SUCRA) scores were used to determine the best-performing reconstruction approach. Fifty vessels were included in the final analysis. CTA showed weak correlation with NIRS-IVUS for FT (ICC <0.43), good correlation for Ca (ICC 0.42-0.83), and poor correlation for NC, except when using reconstruction approach ADMIRE 2, 0.50 ​mm slice thickness, and fixed HU cutoffs, which demonstrated moderate correlation for NC (segment-level ICC ​= ​0.67; lesion-level ICC ​= ​0.61). This approach ranked highest on SUCRA plots. CTA reconstruction parameters influence plaque composition analysis. The combination of an intermediate-strength IR, thin slice thickness, and fixed HU cutoffs yields the most accurate tissue characterization compared to NIRS-IVUS as the reference standard.

20 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
EKElina Khattab
Elina Khattab
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
DKDimitris Karelas
Dimitris Karelas
MIMaria Ioannou
Maria Ioannou
ETEVANGELOS TATSIS
EVANGELOS TATSIS
Nikolaos KadoglouNikolaos Kadoglou
Nikolaos Kadoglou
Background/Objectives: Cardiorenal syndrome (CRS) is associated with substantially higher morbidity and mortality than either isolated cardiac or renal dysfunction. The application of classical and novel biomarkers has been tested in prompt diagnosis and monitoring of patients with CRS. Methods: This is a comprehensive literature review following a structured approach. We searched MEDLINE and Embase databases from January 2000 to December 2025. Results: The pathophysiology of CRS is complex, and the present review attempts to shed light on the clinical interpretation of the most widely used biomarkers as indices of diagnosis and prognosis. Among them, troponin is elevated in CRS and its absolute levels retain prognostic value, while changes in its levels over time may assist in the diagnosis of acute coronary syndrome. Natriuretic peptides are highly influenced by coexistence of chronic kidney disease (CKD) and in this context have considerable diagnostic and prognostic value. The combination of cystatin C, a biomarker of renal dysfunction, with cardiac biomarkers may create a powerful risk algorithm. Most recently, gene profiling and proteomics have the potential to stratify patients with CRS; however, more data from large cohorts are required for their validation. The therapeutic modulation of biomarkers in CRS patients may help elucidate the underlying pathophysiologic mechanisms. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as first-line therapy for patients with CRS, despite the fact their mechanisms are mostly unknown. Significant changes in the aforementioned biomarkers and the inflammatory factors may explain their emerging beneficial effects on both heart failure and CKD. Conclusions: The use of biomarkers has increased rapidly in recent years for diagnosis, surveillance and prognostic stratification in CRS.

27 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
PGPanos Georghiou
Panos Georghiou
AGAmalia Georgiou
Amalia Georgiou
NINikolas Iosif
Nikolas Iosif
FTFilippos Triposkiadis
Filippos Triposkiadis
Cardiovascular disease remains Europe’s leading cause of death and disability despite mature evidence for prevention, acute and chronic treatment, rehabilitation, and secondary prevention. This structured critical narrative review evaluates whether the European Safe Hearts Plan can convert this evidence into coordinated, measurable, and accountable cardiovascular pathways. We appraise the plan’s ten flagship actions by evidence maturity and implementation readiness; distinguish shared system functions from disease-specific delivery for acute coronary syndromes, heart failure, and atrial fibrillation; compare selected European Society of Cardiology and American Heart Association/American College of Cardiology recommendations; and propose a core indicator set and staged Cyprus pilot. Guideline-supported interventions should be standardised and audited, whereas screening technologies, digital health, artificial intelligence, and novel phenotyping require governed implementation and prospective assessment of patient outcomes, costs, equity, and unintended consequences. Cyprus is presented as a bounded implementation setting rather than a directly generalisable European model. The plan should be judged through a limited set of clinical, implementation, and equity indicators, including premature cardiovascular mortality, risk factor control, guideline-directed therapy, rehabilitation participation, registry completeness, reach, and fidelity.

Verified
Journal Article
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
KSKlitia Socratous
Klitia Socratous
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
KLKonstantinos Lampropoulos
Konstantinos Lampropoulos
PGPanos Georghiou
Panos Georghiou
FTFilippos Triposkiadis
Filippos Triposkiadis
Aortitis—inflammation of the aortic wall—presents at the interface of vasculitis, infection, structural aortic disease, and cardiovascular risk. It may occur in giant cell arteritis (GCA), Takayasu arteritis, immunoglobulin G4 (IgG4)-related disease, drug-induced injury, infection, or as an isolated finding after aortic surgery. Modern imaging detects aortic inflammation more frequently, but the main challenge is classification rather than detection: determining whether disease is infectious or immune-mediated, active or dominated by fixed structural damage, systemic or isolated, and whether the dominant threat is aneurysm, dissection, undertreated infection, or avoidable immunosuppression. This review considers aortitis as a high-risk vascular syndrome requiring aetiology-first classification rather than descriptive labelling. Before escalating immunosuppression, infection must be actively excluded and inflammatory activity distinguished from fixed vascular damage. Treatment should be individualised according to phenotype, age, vascular territory, comorbidity, and toxicity risk, with surveillance continuing even after symptoms and inflammatory markers improve. Optimal care depends on multidisciplinary assessment integrating rheumatology, infectious diseases, vascular surgery, radiology, and cardiology expertise. Progress will require standardised imaging definitions, registries linking inflammatory control with structural vascular outcomes, and validation of artificial intelligence (AI) tools before clinical adoption.